Streetbeat News

Analyst Ratings

EYPT

EyePoint Pharmaceuticals (NASDAQ:EYPT) has received diverse analyst ratings over the past quarter, with a shift towards more bullish sentiments in the last 30 days. The average 12-month price target for EYPT has increased by 12.64% to $36.8, with a high estimate of $44.00 and a low estimate of $33.00. Financial analysis reveals a positive revenue trend with a growth rate of 51.84% as of September 30, 2023, but challenges in net margin, ROE, and ROA. The company's debt-to-equity ratio is below industry average, indicating a conservative financial approach.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 8:00 pm

JD

Financial analysts have observed a bullish trend in JD.com's (NASDAQ:JD) options trading, with 68% of trades being bullish. The analysis highlighted 16 unusual trades, with a significant number of calls over puts, indicating a positive sentiment towards JD.com. The price target for JD.com is set between $22.0 and $45.0, based on volume and open interest trends. JD.com's current market status shows a slight decrease in stock price with a potential overbought RSI indication. Market experts have issued a consensus target price of $38.8 for JD.com, with ratings ranging from Neutral to Buy.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 7:45 pm

PHAT

Needham analyst Joseph Stringer has reiterated a Buy rating on Phathom Pharmaceuticals (NASDAQ:PHAT) and maintained a $26 price target.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 7:22 pm

AVGO

GLD

IWM

MRVL

NVDA

SOXX

Stocks experienced a mixed session with the S&P 500 and Nasdaq 100 facing weekly losses. Semiconductor stocks fell sharply due to disappointing guidance from Marvell Technology and Broadcom, affecting the sector's ETFs. Small caps outperformed, and gold reached new highs. Bitcoin saw a brief peak before pulling back. Major indices and ETFs showed varied performance, with technology stocks underperforming. Several companies moved on earnings reports, upgrades, and trial results.

Portfolio Pulse from Piero Cingari

March 08, 2024 | 7:18 pm

RBT

Cantor Fitzgerald analyst Brett Knoblauch has maintained an Overweight rating on Rubicon Technologies (NYSE:RBT) but lowered the price target from $4 to $1.6.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 7:17 pm

RWAY

Ladenburg Thalmann analyst Mickey Schleien downgraded Runway Growth Finance (RWAY) from Buy to Neutral. The downgrade reflects a change in the analyst's outlook on the stock.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 7:10 pm

AMZN

GOOG

MRVL

Marvell Technology Inc (NASDAQ:MRVL) shares fell 9.35% after reporting Q4 results with disappointing guidance. Analysts have mixed reactions, with several raising their price targets despite the guidance. The company's data center growth was highlighted, but concerns were raised about declines in non-data center revenue. AI-related revenue is expected to significantly increase, with Marvell beginning shipments to major customers like Google and AWS. The company's guidance for the next quarter was below consensus, attributed to declines in Carrier Infrastructure, Enterprise Networking, and Consumer segments.

Portfolio Pulse from Priya Nigam

March 08, 2024 | 7:08 pm

ALB

Vertical Research analyst Kevin McCarthy downgrades Albemarle (ALB) from Buy to Hold and sets a $145 price target.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 7:06 pm

BC

Seven analysts have recently updated their ratings on Brunswick (NYSE:BC), showing a shift towards a more bullish outlook with an average 12-month price target of $105.71, up from $95.50. The updates include raised price targets and ratings, reflecting positive sentiment towards Brunswick's market position despite a -13.95% decline in revenue growth and a high debt-to-equity ratio. Brunswick is recognized for its innovation in the marine recreation industry, with a strong market capitalization and financial health indicators like net margin, ROE, and ROA outperforming industry averages.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 7:01 pm

IBM

Recent options activity for International Business Machines Corporation (IBM) shows a bullish trend among investors, with a significant amount of money moving into calls compared to puts. The trading volume and open interest analysis suggest a price target range of $135.0 to $225.0 for IBM. Despite a slight decrease in stock price by -0.92% to $194.73, the company's vast global presence and critical role in IT services and transactions underline its importance. Analysts have a consensus target price of $186.0 for IBM, indicating a cautious outlook.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 7:01 pm